KZR - Kezar Life Sciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-113.6M

Cash

179.8M

Avg Qtr Burn

-20.91M

Short % of Float

2.20%

Insider Ownership

14.84%

Institutional Own.

61.57%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Zetomipzomib (KZR-616) Details Inflammatory disease, Chronic inflammatory disorder, Chronic kidney disease, Kidney disease, Lupus nephritis	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Zetomipzomib (KZR-616) Details Autoimmune Hepatitis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-261 Details Solid tumor/s, Melanoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
KZR-616 Details Chronic inflammatory disorder, Inflammatory disease, Autoimmune disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.